|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||28.91 - 29.10|
|52 Week Range||25.25 - 36.82|
|PE Ratio (TTM)||20.59|
|Forward Dividend & Yield||1.03 (3.58%)|
|1y Target Est||N/A|
This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.
Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.
The U.S. Food and Drug Administration on Thursday approved Roche's Hemlibra, a new medicine for haemophilia A that the Swiss drugmaker is counting on to help to offset eroding sales of older medicines going off patent. The U.S. regulator approved Roche's drug, previously known as ACE910, or emicizumab, as a once-weekly injection for adults and paediatric patients with haemophilia A who have developed inhibitors, or resistance, to other treatments.
The U.S. Food and Drug Administration on Thursday expanded approvals for Roche's Gazyva to include previously untreated follicular lymphoma, bolstering the Swiss drugmaker's efforts to strengthen its portfolio ...
Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.
Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.
Swiss drugmaker Roche on Friday won a key European panel's recommendation for its multiple sclerosis drug Ocrevus, which is on track for nearly $1 billion in sales in 2017 after winning U.S. regulators' go-ahead earlier this year. Ocrevus got a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for treating adult patients with relapsing multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS). Final approval falls to the European Commission, but it generally follows the CHMP recommendation.
Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.
In 3Q17, Roche’s (RHHBY) Gazyva generated revenues of 69 million Swiss francs, which reflected ~34% growth on a year-over-year (or YoY) basis.
In 3Q17, Roche Holding’s (RHHBY) Lucentis generated revenues of 399 million Swiss francs, which reflected ~7% growth on a year-over-year (or YoY) basis.
In 3Q17, Roche Holding’s (RHHBY) Actemra generated revenues of 485 million Swiss francs, which reflected ~13% growth on a year-over-year (or YoY) basis.
In 3Q17, Roche Holding’s (RHHBY) Avastin generated revenues of 1.6 million Swiss francs, which reflected a ~4% fall on a year-over-year (or YoY) basis.
In 3Q17, Roche’s (RHHBY) Herceptin generated revenues of 1.7 billion Swiss francs, which is a 5% fall on a quarter-over-quarter (or QoQ) basis.
In 3Q17, Roche Holding's (RHHBY) Tecentriq generated revenues of 118 million Swiss francs, which reflected ~104% growth on a year-over-year (or YoY) basis.
In 3Q17, Roche Holding (RHHBY) generated revenues of 13.1 billion Swiss francs, which was a ~5% rise YoY. Revenues for its Pharmaceuticals segment rose ~4%, and its Diagnostics segment rose ~6%.
Cancer treatment is moving rapidly toward personalized medicine and precision medicine thanks to genetic insight.
LONDON (Reuters) - Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's (ROG.S) immunotherapy drug Tecentriq is ...
Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.